Mitsubishi Pharma - Database of Clinical Trials by Pharmaceutical Companies

All Categories Pharma Companies » Mitsubishi Pharma

Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease

Condition: Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin
Interventions: Drug: TA-650; Drug: Polyethylene Glycol-treated Human Immunoglobulin (VGIH)
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified May 2012
Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis

Condition: Pediatric Ulcerative Colitis
Intervention: Drug: TA-650
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified April 2012
Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease

Condition: Pediatric Crohn's Disease
Intervention: Drug: TA-650
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified April 2012
Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions

Conditions: Behcet's Disease; Behcet Syndrome; Neuro-Behcet's Disease
Intervention: Drug: TA-650
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified February 2012
A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: TA-7284 Low; Drug: TA-7284 High
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified January 2012
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis

Condition: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Drug: MCI-186; Drug: Placebo; Drug: MCI-186 in open label phase
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified December 2011
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients

Condition: Chronic Hepatitis C
Interventions: Drug: MP-424 (generic name:Telaprevir); Drug: Ribavirin; Drug: Peginterferon alfa-2b
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified November 2011
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

Condition: Chronic Hepatitis C
Interventions: Drug: MP-424 (generic name:Telaprevir); Drug: Ribavirin; Drug: Peginterferon alfa-2b
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified November 2011
A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

Condition: Perennial Allergic Rhinitis
Interventions: Drug: TAU-284; Drug: TAU-284; Drug: Placebo
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Completed - verified March 2012
Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: TA-7284 Low; Drug: TA-7284 High; Drug: Placebo
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Active, not recruiting - verified February 2012
Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: TA-7284-Low; Drug: TA-7284-High
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Active, not recruiting - verified February 2012